Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Colonoscopy Dye Tablets Boost Polyp Detection Rate

By MedImaging International staff writers
Posted on 19 Jun 2018
Ingestion of the delayed-release methylene blue dye (MMX) tablet during bowel preparation for colonoscopy increases adenoma detection rate (ADR), claims a new study.

Researchers at Humanitas University Medical School (Milan, Italy), Mayo Clinic Florida (Jacksonville, USA), and other institutions conducted a study involving 1,205 patients scheduled for colonoscopy at 20 centers worldwide, randomly assigning patients to one of three groups: Those who received a full dose of oral MMX during colonoscopy preparation; patients who received a placebo during preparation; and a group of patients who received a half dose of MMX. The third group was used to make it harder for participating physicians to know which patients were in the active group.

The results revealed that patients who received the full 200 mg dose of MMX had 56.3% detection rate of adenomas and carcinomas; in the placebo group, the detection rate was 47.8%. Flatter and smaller lesions--less than 5 millimeters in diameter--were found in patients who received the full dose of MMX. When excluding the expected effects of blue feces and urine discoloration, less than 6% of the patients experienced other mild adverse effects when taking the tablet. The study was presented at the annual Digestive Disease Week (DDW), held during June 2018 in Washington (DC, USA).

“Identification of cancerous and pre-cancerous lesions is of utmost importance to prevent colorectal cancer,” said lead author and study presenter professor of gastroenterology Alessandro Repici, MD, of Humanitas University Medical School. “Our study, which used the highest standard of care, allowed gastroenterologists to better detect and remove difficult-to-see polyps, which has great implications for further preventing this disease.”

“While utilizing blue dye to increase ADR is not a new concept, the fact that this technology now comes in tablet form is a major advance,” said senior author Professor Michael Wallace, MD, MPH, of Mayo Clinic Florida, and a primary investigator on the Phase III trial of MMX. “Our research shows the oral delayed-release methylene blue provides gastroenterologists with a new means to improve their ADR, with no additional inconvenience or safety risks to the patient and no supplemental time required to the endoscopist.”

Methylene blue is both a medication and a dye. As a medication, it is used to treat methemoglobin levels greater than 30% or in which there are symptoms despite oxygen therapy. Methylene blue is also used as a thiazine dye, which works by converting the ferric iron in hemoglobin to ferrous iron. While usually given in injected form, the tablet form, MMX, is under development by Cosmo Pharmaceuticals (Dublin, Ireland; www.cosmopharma.com). The tablets are coated with pH-resistant acrylic copolymers, which delay the release until the tablet reaches the indicated intestinal location where the programmed dissolution begins.

Related Links:
Humanitas University Medical School
Mayo Clinic Florida


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
X-Ray QA Meter
Piranha CT
New
Enterprise Imaging & Reporting Solution
Syngo Carbon
Color Doppler Ultrasound System
DRE Crystal 4PX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to MedImaging.net and get complete access to news and events that shape the world of Radiology.
  • Free digital version edition of Medical Imaging International sent by email on regular basis
  • Free print version of Medical Imaging International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of Medical Imaging International in digital format
  • Free Medical Imaging International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Ultrasound

view channel
Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)

Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease

Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more

Nuclear Medicine

view channel
Image: Researchers have identified a new imaging biomarker for tumor responses to ICB therapy (Photo courtesy of 123RF)

New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy

Immunotherapies, such as immune checkpoint blockade (ICB), have shown promising clinical results in treating melanoma, non-small cell lung cancer, and other tumor types. However, the effectiveness of these... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.